Main Inclusion Criteria:
Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
Male or female aged ≥ 18 years.
Relapsed/refractory patients with histologically or cytologically confirmed diagnosis of advanced-stage or recurrent cancer
Progressed on/relapsed after at least one prior anti-PD-1/PD-L1 treatment
Biopsy-accessible tumor lesions and willing to undergo triple sequential tumor biopsy (Part A).
At least 1 radiologically measurable lesion per RECIST V1.1/imRECIST (Part B).
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Life expectancy > 3 months as assessed by the Investigator.
Adequate organ function (bone marrow, hepatic, renal function and coagulation).
Main Exclusion Criteria:
Pregnant or breastfeeding.
Any tumor-directed therapy within 21 days before study treatment.
Treatment with investigational agent within 21 days before study treatment.
Radiotherapy within 14 days before study treatment.
Pre-existing arrhythmia, uncontrolled angina pectoris, uncontrolled heart failure (NYHA II-IV), any myocardial infarction/coronary event, CNS-ischemic event and any thromboembolic event at any time < 6 months prior to Screening.
Left ventricular ejection fraction (LVEF) < 50% measured by echocardiogram or MUGA.
QTcF > 450 ms for men or > 470 ms for women.
Any active autoimmune requiring systemic immunosuppressive treatments. .
Any history of non-infectious pneumonitis < 6 months prior to Screening.
Any active inflammatory bowel disease such as Crohn's disease or ulcerative colitis which are generally excluded or active autoimmunthyroiditis present < 6 months prior to Screening.
History of CNS disease such as stroke, seizure, encephalitis, or multiple sclerosis (< 6 months prior to Screening).